BMY (BMS) Rentabilitas dodolan miturut bathi reged

BMY (BMS) - tandha merek perusahaan

Leveraging a strong roster of scientists and R&D achievements to combat the patent cliff, Bristol-Myers Squibb (BMY) is expanding its oncology portfolio. The relative gross margin visualizes current production costs, where 66.30 determines the latest valuation metric. The business is currently investing in new molecules to maintain its market position and effectively counter the expansion of affordable generic manufacturers.

BMY Tingkat bathi miturut bathi reged Bristol-Myers Squibb Co. (04.07.2022 - 20.11.2026)

Rincian analitis lan laporan data perusahaan Bristol-Myers Squibb (BMY)

Ringkesan analisis perusahaan:BMY (Bristol Myers Squibb Company)
Produk mawa merek Bristol-Myers Squibb Co.

Gross margin determines the portion of revenue remaining after covering direct production costs. This ratio measures cost management efficiency, allowing for the real-time assessment of price fluctuations bypassing smoothed quarterly reports. By analyzing gross profit margins, an investor evaluates the stability of the operational foundation. For Bristol-Myers Squibb (BMY), this metric is critical when updating the portfolio through M&A and replacing expiring patents with new developments.